Additionally, the overall infection burden, rather than solely genitourinary-specific infection burden, contributed to these long-term changes, possibly implying a role for the cumulative burden of infections in prostate cancer risk.
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| INTRODUCTION
Inflammation elicited by sexually transmitted infections (STIs) has long been considered to play a role in prostate cancer (PCa) development. 1 Although symptomatic, STI-mediated prostate inflammation (ie, acute and chronic bacterial prostatitis) is now rare and thus of possibly lesser relevance for PCa development, we have documented that asymptomatic, STI-mediated prostate inflammation still occurs, even in the current antibiotic era. Specifically, we observed that young infected men in two of our previous studies, one STI-clinic 2 and one U.S.
military-based, 3 were significantly more likely to have a large rise in their concentration of serum prostate-specific antigen (PSA), which we used as a marker of prostate inflammation and cell damage, at the time of their infection than controls. These findings suggest that as many as 25-30% of infected men had asymptomatic prostate infection. 2, 3 Interestingly, in the first of these studies, men's convalescent PSA concentrations remained elevated for at least several months after diagnosis and effective antibiotic therapy, raising the possibility of a longer-term influence of STIs on the prostate. 2 These findings are consistent with those from cross-sectional studies of Chlamydia trachomatis (CT) 4 and human herpesvirus type 8 serology 5, 6 that observed positive results with PSA, as well as those from longitudinal studies of men treated for febrile urinary tract infections (UTIs) that observed large PSA rises sustained over several months. 7, 8 In addition to genitourinary infections, non-genitourinary and systemic infections have also been found to contribute to elevated serum PSA. In our previous study of young US military members, we found that serum PSA rose during episodes of adult-onset infectious mononucleosis (IM) and other systemic infections, 3 and remained higher than their baseline concentrations even after levels of high sensitivity C-reactive protein, a marker of systemic inflammation, fell. 9 Elevated PSA concentrations were also observed in a case report of a man with Chikungunya virus infection. 10 Together with findings for genitourinary tract infections, these results suggest that many types of infections may influence the prostate, either directly through prostate infection or indirectly through possible mechanisms such as local genitourinary-or systemic inflammation-mediated cell damage, leading to chronic prostate inflammation. These findings also suggest that the influence of infections may be sustained over a period of at least a few months to 1 year. 11 To extend our previous findings and determine whether PSA changes are sustained over longer periods of time, we measured PSA concentration in specimens collected early in young U.S. military men's careers and specimens collected an average of 10 years later from the same cases and controls as our previous U.S. military-based study of infections and PSA. 3, 11 We used these concentrations to examine the influence of the individual and cumulative burden of STIs, IM, and other systemic infections on long-term PSA change. We focused on younger men because they are at higher risk of STIs and because they may be more susceptible to carcinogenic exposures, 12 having completed prostate development and maturation more recently.
PSA concentrations in young men in their thirties and forties have also been found to predict later PCa development, [13] [14] [15] [16] suggesting that our study may inform not only the long-term influence of infections on the prostate, but also their influence on PCa risk. 2004-6. We used specimens collected in the 2nd and 3rd windows for our previous analysis of the short-term influence of infections on PSA, 3, 11 and specimens collected in the 1st and 4th windows for our current analysis (Figure 1 ). Availability of specimens in all four windows ensured that participants could be included in both analyses. Finally, we combined all previously described case types (a priori specified exudative STI and IM cases, and post hoc derived nonexudative STI, genitourinary infection/inflammatory condition, and systemic infection cases) into a further case group (any infection/ inflammatory condition) to investigate the influence of any infection or inflammatory genitourinary condition on PSA change, as well as the number of these infections/conditions. Controls for these post hoc analyses were defined as men who did not meet the definition for any of the case groups (n = 125). We did not report findings for the nonexudative STI and genitourinary case groups separately because the sample sizes for these groups were too small for statistical model Exudative sexually transmitted infection (STI) cases were defined as men with at least one laboratory-confirmed diagnosis of genital chlamydia, gonorrhea, or non-chlamydial, non-gonococcal urethritis during the 3rd time window. Infectious mononucleosis (IM) cases were defined as men with a diagnosis of IM in either the 2nd or 3rd time window to achieve a larger sample size for this less common diagnosis. Controls were required to be free of STI and IM diagnoses in all four time windows. Specimens collected in the 2nd and 3rd time windows were used to examine the acute influence of infections on PSA, 3, 11 whereas specimens collected in the 1st and 4th time windows were used to examine the longer-term influence of infections on PSA in the current analysis. Additional post hoc case groups were also created to examine the longer-term influence of other infections (eg, systemic infections) occurring in any of the four time windows on PSA. This figure is not drawn to scale on the yaxis and PSA concentration is solely depicted as a visual representation of study sampling methodology convergence; therefore, their contribution was limited to the combined any infection/inflammatory condition analysis.
| PSA testing
For each case and control, we measured serum total PSA concentration in two specimens: 1) the earliest specimen collected in the 1st window ("baseline specimen") and 2) the latest specimen collected in the 4th window ("follow-up specimen") to maximize follow-up. PSA was measured rather than abstracted from participants' military medical records because participants were too young (ages 18-27 at baseline specimen collection) for PSA-based prostate cancer screening and thus did not have PSA measurements in their medical record.
Instead, we measured PSA at the Johns Hopkins Medical Hospital using the Access Hybritech PSA assay (Beckman Coulter). Concentrations below 0.01 ng/mL, the lower limit of detection for the Hybritech assay were imputed to 0.01 ng/mL (n = 8). PSA assay reproducibility was tested by including 25 blinded quality control pairs from the DoDSR in the testing sequence (coefficient of variation = 12.4% and 6.9% after excluding one discrepant pair).
| Statistical analysis
We followed the same analysis plan for each case type of interest. We first explored the influence of case diagnoses on long-term PSA change by calculating arithmetic and geometric mean baseline and follow-up PSA concentrations for cases and controls. We compared these values by linear regression with robust variance estimation to take repeated measures from the same participant into account (ie, baseline and follow-up specimens). All models included adjustment for race to account for frequency matching. We also assessed any long-term shifts in the distribution of PSA change between the baseline and follow-up specimens for cases and controls by calculating proportions of race-adjusted categories of absolute and relative PSA change by linear regression, and then by comparing these distributions by logistic regression. Absolute PSA change was defined by 0.10 ng/mL categories ranging from 0.00 to 0.50 ng/mL, and relative percent change categories were defined by 20% increases in PSA ranging from 0% to 100%. Although large relative rises in PSA (≥40%) similar to those observed in our studies of the short-term influence of acute infections on PSA were not expected in this longer-term analysis, we explored large rises (≥40% increase in PSA from the baseline to followup specimens) in this analysis as well. Finally, we compared the percentage of cases and controls whose PSA rose to any degree (>0 ng/mL) between their baseline and follow-up specimens, also using linear and logistic regression. 
| RESULTS
In our sample of active duty U.S. military men, exudative STI cases (CT, GC, and NCNGU) were slightly younger and less likely to be married at the time of their baseline specimen collection than controls. They were also more likely to be enlisted, to have served in an active combat country (Afghanistan or Iraq) during follow-up, to have had their baseline specimen collected later in follow-up (1996-7) and to have a greater number of blood draws for HIV-1 testing during follow-up (Table 1) . Although all exudative STI and IM cases were frequencymatched to controls by race as a group, distributions of individual STI types varied by race (ie, GC cases were more likely to be AfricanAmerican and IM cases were more likely to be White than controls).
Baseline PSA concentrations ranged from <0.01 to 9.12 ng/mL, with median concentrations ranging from 0.46 to 0.59 ng/mL. Similar PSA concentrations were observed across all study groups (cases and controls) at baseline (Figure 2 ).
| Exudative STIs
CT and NCNGU cases had a slightly greater increase in PSA over time than controls, as evidenced by greater mean and geometric mean changes in PSA, and greater proportions of those with large relative rises (>40%) and rises of any magnitude in PSA; however, none of these differences was statistically significant (Table 2 ). No differences were observed between GC cases and controls. When all exudative STI case groups were combined, similar findings were observed as in the individual CT and NCNGU analyses, except that the difference for a rise in PSA of any magnitude was significant with the larger combined sample size (67.7% vs 60.8%, P = 0.043).
We also investigated whether the number of exudative STI episodes influenced long-term PSA change (Supplementary Table S2 Null findings were observed when the number of exudative STIs was examined separately by type (eg, multiple episodes of CT only, data not shown), although small sample sizes limited interpretation of these results.
| IM and other systemic infections
IM and other systemic infection cases had a slightly greater increase in PSA over time than controls (Table 3 ). This change was evident both by non-significantly greater mean and geometric mean changes in PSA, as well as by a greater likelihood of a rise in PSA of any magnitude during follow-up (IM: 70.6% vs 60.8%, P = 0.062; other systemic infections:
66.7% vs 54.4 %, P = 0.047). Other systemic infection cases were also non-significantly more likely to have a large relative rise in PSA during follow-up than controls (32.4% vs 23.0% P = 0.062).
| Any infection
Finally, we estimated the influence of the cumulative burden of infections on PSA (Table 4 ). This analysis included men with a history of exudative STIs, who formed the largest part of the case group, as well as smaller numbers of men with non-exudative STIs, IM, genitourinary infections and inflammatory conditions, and systemic infections.
Overall, men with any of these infections had significant positive shifts in their absolute (P = 0.010) and relative (P = 0.0004) 1 Values for cases and controls were calculated by linear regression adjusting for race (African-American and non-African-American), except for values for the race variable. All p-values refer to comparison of the respective case group to controls and were calculated by linear regression for continuous or binary variables and by logistic regression for categorical variables, and included adjustment for race. P-values for race were calculated by the chi-square test. 2 Case types are mutually exclusive with the exception of the any infection case group. 3 Controls for this analysis had no history of infection during follow-up (N = 125). 4 Chlamydia, gonorrhea, NCNGU, and IM cases were frequency-matched as a group to controls by race/ethnicity. distributions of serum PSA from baseline to follow-up compared to controls. Also, they were non-significantly more likely to have a large Values were estimated by linear regression with robust variance estimation for continuous variables and by linear regression for binary and categorical variables. All models were adjusted for race (African-American, non-African American) to account for frequency matching.
3 P values were calculated by linear regression with robust variance estimation for continuous variables and by logistic regression for categorical variables. All models were adjusted for race to account for frequency matching.
We previously hypothesized that PSA elevation may be more evident for some STIs than others (eg, CT more than GC) because CT presents more often as an asymptomatic infection than GC, 23 and thus may persist undiagnosed and untreated for a period of longer time, allowing for sustained damage to the prostate epithelium. This mechanism might also apply to sexually transmissible infections that have been detected in prostate tissue but have other dominant non-sexual modes of transmission (eg, Epstein-Barr virus infection). In contrast to the above-described direct prostate-specific mechanism for PSA elevation, mechanisms for non-genitourinary, systemic infections, such as varicella, are likely less direct. We previously proposed that these infections may contribute to elevated PSA by several possible mechanisms, including systemic inflammation-mediated prostate cell damage and increased vascular permeability, or increased vascular permeability in the context of preexisting prostate epithelial cell damage/disruption from other sources. 11 In addition, once infection has resolved, PSA could possibly remain elevated for months to years later for a number of reasons, including chronic inflammation against residual infectious antigens, continued healing, delayed or impaired ability to counteract future prostate insults, or broken tolerance to self-prostatic antigens, 2 all of which could possibly amplify with repeated infections over time.
Irrespective of the mechanism by which infections raise PSA, a key question that remains to be addressed is the meaning of this elevation for prostate cancer risk. Although we did not observe many PSA values above recommended biopsy thresholds (2.5 or 4.0 ng/mL 24 ), we did still observe that infections were associated with a greater likelihood of an increase in PSA over the 10-year period from men's twenties to thirties. This small increase may be important because higher than average PSA concentrations in young to mid-adulthood have been Values were estimated by linear regression with robust variance estimation for continuous variables and by linear regression for binary and categorical variables. All models were adjusted for race (African-American, non-African American) to account for frequency matching.
found to predict future prostate cancer risk and aggressiveness. [13] [14] [15] [16] For instance, in two previous studies of young men ages 40-49, those with PSA concentrations above the median (∼0.6-0.7 ng/mL) had a 4-7 fold increase in future prostate cancer risk compared to those below the median. 16, 25 For comparison in our study, 15.5% of systemic infection cases had PSA concentrations higher than 0.7 ng/mL at the end of follow-up compared to 9.3% of controls.
Therefore, it is conceivable that this small difference in PSA could translate into a large difference in prostate cancer detection or risk, consistent with the hypothesis that persistent or repeated prostate epithelial cell damage and regeneration (the "injury and regeneration" hypothesis) increases the risk of cellular transformation and prostate carcinogenesis. 26 As a further more troubling possibility, it is also conceivable that infections could contribute to an increase in the trajectory of PSA (ie, a higher slope or rate of change), particularly if these insults occur during adolescence and young adulthood when the prostate is still growing and developing, and thus may be more susceptible to carcinogenic exposures. 12 This type of increase might lead men to reach higher PSA concentrations than they would otherwise reach without infections, or to reach these concentrations at younger ages.
To our knowledge, this study is the first to prospectively examine the influence of infections on long-term PSA change, as previous studies have looked either only cross-sectionally 4, 21, 27 or directly following an acute infection. optimal circumstances, we would have defined systemic infections in a more expansive manner for our post hoc analyses, but were limited by the STI focus and design of our primary analysis. However, even with this narrower focus, our interesting findings for systemic infections provide the rationale to explore the impact of these infections further on prostate cancer risk.
| CONCLUSIONS
In summary, we found that young men with histories of both genitourinary (CT, GC, and NCNGU) and non-genitourinary infections were more likely to have an increase in PSA of any magnitude over an average of 10 years of follow-up than controls. These findings raise the possibility that overall infection burden, rather than solely genitourinary-specific infection burden, may contribute to prostate cancer risk.
